成都苑东生物制药股份有限公司 独立董事关于第三届董事会第十二次会议 相关事项的独立意见 我们作为成都苑东生物制药股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券交易所科创板 股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《公司章程》 及公司《独立董事工作制度》等有关规定，本着对公司、全体股东及投资者负责 的态度，基于独立判断的立场，对公司第三届董事会第十二次会议审议的《关于 <公司 2023 年半年度募集资金存放与使用情况的专项报告>的议案》发表独立意 见如下： 报告期内，公司募集资金存放与使用情况符合《上海证券交易所科创板股票 上市规则》、《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号—— 规范运作》等法律法规和公司《募集资金管理制度》等制度文件的规定；公司对 募集资金进行了专户存储和专项使用，使用部分闲置募集资金进行现金管理事项 已履行了必要且合规的决策程序，并及时履行了相关信息披露义务，不存在变相 改变募集资金用途和损害股东利益的情况，不存在违规使用募集资金的情形。因 此，我们一致同意该议案。 独立董事：JIN L ...

证券代码：688513 证券简称：苑东生物 公告编号：2023-031 成都苑东生物制药股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一）回购股份的目的和用途 风险提示： 1 拟回购股份的用途：公司拟在未来适宜时机使用本次回购的股份实施员工 持股计划或股权激励，并在股份回购实施结果暨股份变动公告披露后三年 内完成股份转让；若公司未能在规定期限内转让完毕，则将依法履行减少 注册资本的程序，未转让的股份将被注销。 拟回购价格：不超过人民币 73 元/股（含），该价格不高于公司董事会通过 回购决议前 30 个交易日公司股票交易均价的 150%。 拟用于回购股份的资金总额：不低于人民币 10,000 万元（含）且不超过人 民币 20,000 万元（含）。 回购期限：自董事会审议通过回购股份方案之日起 12 个月内。 回购资金来源：公司自有资金。 相关股东是否存在减持计划：截至本公告披露之日，公司控股股东、实际 控制人及其一致行动人、公司董事、监事及高级管理 ...

成都苑东生物制药股份有限公司 独立董事关于第三届董事会第十一次会议 相关事项的独立意见 我们作为成都苑东生物制药股份有限公司（以下简称"公司"）的独立董事， 根据《中华人民共和国公司法》（以下简称《公司法》）、《上海证券交易所科创板 股票上市规则》、《关于在上市公司建立独立董事制度的指导意见》、《公司章程》 及公司《独立董事工作制度》等有关规定，本着对公司、全体股东及投资者负责 的态度，基于独立判断的立场，对公司第三届董事会第十一次会议审议的《关于 以集中竞价交易方式回购股份方案的议案》发表独立意见如下： 1、公司本次回购股份符合《公司法》、《证券法》以及《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等法律法规、规范性文件以及《公司 章程》等有关规定，回购股份的审议和决策程序合法合规。 2、公司本次回购股份的用途为员工持股计划或股权激励，有利于充分调动 公司员工的积极性，提高团队凝聚力和竞争力，有效地将股东利益、公司利益和 员工利益紧密结合，促进公司稳定、健康、可持续发展，因此，本次股份回购具 有必要性。 3、本次回购资金来源为公司自有资金，不会对公司的经营、财务和未来发 展产生重大影响，公司 ...

证券代码：688513 证券简称：苑东生物 公告编号：2023-030 成都苑东生物制药股份有限公司 第三届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第三届董事会第十一次会 议于 2023 年 8 月 14 日以现场和通讯相结合的方式召开。会议通知已于 2023 年 8 月 11 日送达全体董事。本次会议由董事长王颖主持，应出席董事 9 名，实际 出席董事 9 名。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 等相关法规和《成都苑东生物制药股份有限公司章程》规定，会议形成的决议合 法有效。 二、董事会会议审议情况 经与会董事审议，形成决议如下： （一）审议通过《关于以集中竞价交易方式回购股份方案的议案》 经审议，董事会认为：公司本次回购股份是基于对公司未来发展的信心和对 公司长期投资价值的认可，有利于充分调动公司员工的积极性，提高凝聚力，有 效地将股东利益、公司利益和员工个人利益紧密结合在一起，促进公司稳定 ...

2023 年第一季度报告 证券代码：688513 证券简称：苑东生物 成都苑东生物制药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 | | --- | --- | --- | | | | 增减变动幅度(%) | | 营业收入 | 277,853,183.77 | 3.31 | | 归属于上市公司股东的净利润 | 60,985,871.41 | 13.35 | | 归属于上市公司股东的扣除非 | 46,330,538.34 | 10.63 | | 经常性损益 ...

Financial Performance - The company's operating revenue for 2022 was approximately CNY 1.17 billion, representing a 14.43% increase from CNY 1.02 billion in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately CNY 246.52 million, a 6.06% increase from CNY 232.43 million in 2021[23]. - The net profit after deducting non-recurring gains and losses was approximately CNY 164.70 million, reflecting a 20.16% increase from CNY 137.07 million in 2021[23]. - The company's total assets at the end of 2022 were approximately CNY 3.02 billion, an 8.73% increase from CNY 2.78 billion at the end of 2021[23]. - The basic earnings per share for 2022 was CNY 2.05, a 5.67% increase from CNY 1.94 in 2021[24]. - The company's net assets attributable to shareholders at the end of 2022 were approximately CNY 2.44 billion, a 6.67% increase from CNY 2.29 billion at the end of 2021[23]. - The total revenue for the reporting period reached ¥60,841.99 million, with a net profit of ¥12,454.41 million, reflecting a significant increase in performance[89]. - The company achieved total revenue of CNY 1,170,512,900.63, representing a year-on-year growth of 14.43%[113]. - The net profit attributable to shareholders was CNY 246,520,800, reflecting a year-on-year increase of 6.06%[113]. Research and Development - Research and development expenses accounted for 22.65% of operating revenue in 2022, up from 20.41% in 2021[24]. - The total R&D investment for the year reached ¥265.14 million, an increase of 27.02% compared to the previous year[74]. - The proportion of R&D investment to operating income rose to 22.65%, up by 2.24 percentage points from the previous year[74]. - The company has over 10 Class 1 innovative drugs in research, with 3 currently undergoing clinical trials, including the oral long-acting hypoglycemic drug, Yograstatin tablets[50][51]. - The company is focusing on innovative drug formulation techniques, achieving a stable production process for EP-0112T, a nasal spray with significant technical challenges[91]. - The company has reported a total R&D investment of 81,481.69 million RMB, representing 29.38% of its operating revenue, which is significantly higher than the industry average[173]. - The company's R&D investment as a percentage of net assets was 10.85%, indicating a strong commitment to innovation and development[173]. - The company capitalized 12.96% of its R&D expenditures, reflecting a strategic approach to managing its research investments[173]. Market Position and Strategy - The company has a strong market position, with three of its main products ranking first in market share, including sodium namifen injection, ibuprofen injection, and ibandronic acid sodium injection[62]. - The company is focusing on building a differentiated competitive advantage in innovative drug products, particularly in the fields of anesthesia and oncology[36][37]. - The company is actively expanding its international presence, particularly in the opioid detoxification and emergency medication product lines[55]. - The company is focusing on integrating raw materials and formulations to ensure supply chain security amid global uncertainties and increasing competition in the biopharmaceutical sector[65]. - The company is strategically expanding its CMO/CDMO business to enhance profitability and strengthen its integrated supply chain capabilities[98]. - The company aims to maintain competitiveness under centralized procurement policies by enhancing operational efficiency and continuously launching new products[146]. - The company is focusing on expanding its product portfolio with new drug approvals and ongoing clinical trials for various therapeutic areas[160]. Risks and Compliance - The company has detailed various risks and countermeasures in its annual report, urging investors to pay attention to investment risks[4]. - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors[7]. - The company faces risks from national volume-based procurement and medical insurance payment adjustments, which may lead to price reductions for some products[105]. - The company has implemented a complete quality management system from drug development to commercial production, ensuring strict quality control[99]. Corporate Governance - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures for providing guarantees[9]. - The company has not reported any instances of more than half of the board members being unable to guarantee the authenticity of the annual report[9]. - The company has not disclosed any special arrangements for corporate governance[9]. Internationalization and Innovation - The internationalization strategy has seen the completion of 2 ANDA submissions, with the hydrochloride injection of Nalfurafine and Nicardipine receiving priority review and acceptance from the FDA[39][40]. - The company has successfully passed the Korean MFDS certification and FDA inspections for raw materials, marking significant progress in internationalization[43]. - The company is committed to internationalization, with plans to complete five international registration projects and enhance its product pipeline for the U.S. market[198]. - The company is focusing on innovation and the development of next-generation biotechnologies to enhance its product offerings[191]. Financial Management - Government subsidies accounted for CNY 65,927,300, which is 25.16% of the total profit, indicating potential risk if policies change[112]. - Operating costs increased by 36.77% year-on-year, primarily due to higher product sales volumes[115]. - The company's investment activities generated a net cash outflow of CNY 405,702,351.20, primarily due to increased construction investments[115]. - The net cash flow from financing activities improved to ¥39,696,297.46 from -¥56,396,555.50, mainly due to increased short-term borrowings and discounted notes receivable[136]. Talent Development - The company has established a comprehensive talent development strategy, including the establishment of a Shanghai Research Institute to attract top talent and enhance innovation capabilities[46]. - The company has a research and development team of over 400 people and has established a national-level enterprise technology center and postdoctoral research workstation[95]. - The R&D personnel count increased to 407, representing 30.76% of the total workforce, with an average salary of ¥23.11 million per person[94].

证券代码：688513 证券简称：苑东生物 公告编号：2023-017 成都苑东生物制药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三） 会议召开方式：上证路演中心网络互动 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 13 日 发布公司 2022 年年度报告及 2022 年度利润分配预案，为加强与投资者的深入交 流，使投资者更加全面、深入地了解公司经营成果、财务指标等情况，公司计划 于 2023 年 04 月 21 日（星期五）上午 11:00 - 12:00 举行 2022 年度业绩暨现金分 红说明会，就投资者关心的问题进行交流，欢迎广大投资者积极参与。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果、 财务指标及 2022 年度现金分红的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （ ...

证券代码：688513 证券简称：苑东生物 成都苑东生物制药股份有限公司 2022 年 4 月投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：688513 证券简称：苑东生物 成都苑东生物制药股份有限公司 2022 年 4 月投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's revenue for Q3 2022 was ¥322,179,501.72, representing a year-over-year increase of 17.27%[6] - Net profit attributable to shareholders for Q3 2022 was ¥60,856,356.20, showing a decrease of 11.46% compared to the same period last year[6] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥38,517,219.50, an increase of 21.54% year-over-year[6] - Total operating revenue for the first three quarters of 2022 reached ¥897,590,018.32, an increase of 16.1% compared to ¥773,436,181.18 in the same period of 2021[24] - Net profit for the first three quarters of 2022 was ¥195,492,474.81, representing a growth of 5.5% from ¥186,075,903.15 in 2021[31] - Basic earnings per share for Q3 2022 were ¥0.51, down 10.53% compared to the same period last year[10] - Basic earnings per share for the first three quarters of 2022 were ¥1.63, compared to ¥1.55 in the same period of 2021[33] Research and Development - R&D investment totaled ¥75,772,263.90 in Q3 2022, up 41.55% from the previous year, accounting for 23.52% of revenue[10] - Research and development expenses for the first three quarters of 2022 amounted to ¥165,078,988.64, up 11.6% from ¥147,822,178.55 in the previous year[27] Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥3,003,472,092.39, an increase of 8.22% from the end of the previous year[10] - The company's total current liabilities increased to ¥563,972,583.20 from ¥432,458,963.97, which is an increase of approximately 30.4%[22] - The total liabilities as of the end of the reporting period were ¥609,933,988.70, an increase from ¥483,601,755.82 in the previous year[24] - The total equity attributable to shareholders reached ¥2,393,538,103.69, up from ¥2,291,664,728.59 in 2021[24] Cash Flow - The company reported a net cash flow from operating activities of ¥141,346,062.05 for the year-to-date period, a decrease of 2.09% year-over-year[10] - Cash inflow from operating activities totaled ¥981,016,081.53 in the first three quarters of 2022, an increase from ¥909,989,358.80 in 2021[36] - The net cash flow from operating activities was $141,346,062.05, a decrease from $144,363,177.82 in the previous period[37] - Cash outflow from investing activities totaled $2,310,797,186.24, down from $3,297,696,338.54 year-over-year[37] - The net cash flow from investing activities was -$673,657,053.10, an improvement from -$943,287,000.18 in the prior period[37] - Cash inflow from financing activities amounted to $147,373,150.35, compared to $10,000,000.00 previously[37] - The net cash flow from financing activities was $52,188,019.78, a recovery from -$76,362,236.06 in the last period[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,138[13] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 2.57%, a decrease of 0.54 percentage points year-over-year[10] - Government subsidies recognized in Q3 2022 amounted to ¥17,921,133.78, contributing to non-recurring gains[10] - The company's cash and cash equivalents decreased to ¥559,858,478.86 from ¥1,050,695,494.02 year-over-year, representing a decline of approximately 46.8%[19] - The trading financial assets increased significantly to ¥766,076,763.67 from ¥453,840,935.17, marking an increase of approximately 68.8%[19] - Accounts receivable rose to ¥137,554,068.67 from ¥112,427,878.56, reflecting an increase of about 22.3%[19] - The company's inventory increased to ¥123,781,058.87 from ¥103,682,790.76, representing an increase of about 19.4%[19] - The company's long-term equity investments were recorded at ¥98,030,208.71, with no previous year data available for comparison[22] - The company reported a significant increase in other non-current financial assets, totaling ¥22,000,000.00, with no previous year data available[22] Business Developments - The company has not reported any significant new product developments or market expansions during the reporting period[16] - There were no significant mergers or acquisitions disclosed in the third quarter report[16]